Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 12, Décembre 2011
Page(s) 1097 - 1105
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20112712016
Publié en ligne 23 décembre 2011
  1. Sadler JE. Von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 2008 ; 112 : 11–18. [CrossRef] [PubMed]
  2. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloprotease family. Blood 2001 ; 98 : 1662–1666. [CrossRef] [PubMed]
  3. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001 ; 276 : 41059–41063. [CrossRef] [PubMed]
  4. Soejima K, Mimura N, Hirashima M, et al. A novel metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001 ; 130 : 475–480. [CrossRef] [PubMed]
  5. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 ; 413 : 488–494. [CrossRef] [PubMed]
  6. Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005 ; 85 : 780–788. [CrossRef] [PubMed]
  7. Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS13. J Thromb Haemost 2006 ; 4 : 1396–1404. [CrossRef] [PubMed]
  8. Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005 ; 3 : 2536–2544. [CrossRef] [PubMed]
  9. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 ; 87 : 4223–4234. [PubMed]
  10. Tsaï HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 ; 87 : 4235–4244. [PubMed]
  11. Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999 ; 81 : 8–13. [PubMed]
  12. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand’s disease. Blood 1998 ; 91 : 2032–2044. [PubMed]
  13. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005 ; 280 : 71773–71778. [CrossRef] [PubMed]
  14. Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelia cell surface. Blood 2004 ; 103 : 2150–2156. [CrossRef] [PubMed]
  15. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004 ; 101 : 10578–10583. [CrossRef]
  16. Majerus EM, Zheng XL, Tuley EA, Sadler JE. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003 ; 278 : 46643–46648. [CrossRef] [PubMed]
  17. Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003 ; 102 : 3232–3237. [CrossRef] [PubMed]
  18. Zhang P, Pan W, Rux AH, et al. The cooperative activity between the carboxy-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007 ; 110 : 1887–1894. [CrossRef] [PubMed]
  19. Davis AK, Makar RS, Stowell CP, et al. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009 ; 49 : 206–213. [CrossRef] [PubMed]
  20. Zanardelli S, Chion AC, Groot E, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 2009 ; 114 : 2819–2828. [CrossRef] [PubMed]
  21. Tao Z, Wang Y, Choi H, et al. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood 2005 ; 106 : 141–143. [CrossRef] [PubMed]
  22. Gao W, Anderson PJ, Majerus EM, et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA 2006 ; 103 : 19099–19104. [CrossRef]
  23. Veyradier A, Girma JP. Assays of von ADAMTS13 activity. Semin Hematol 2004 ; 41 : 41–47. [CrossRef] [PubMed]
  24. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005 ; 129 : 93–100. [CrossRef] [PubMed]
  25. Tripodi A, Chantarangkul V, Böhm M, et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004 ; 2 : 1601–1609. [CrossRef] [PubMed]
  26. Kremer-Hovinga J, Mottini M, Lämmle B. Measurement of ADAMTS13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006 ; 4 : 1146–1148. [CrossRef] [PubMed]
  27. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001 ; 98 : 2730–2735. [CrossRef] [PubMed]
  28. Schmugge M, Dunn MS, Amankwah KS, et al. The activity of the von Willebrand factor-cleaving protease ADAMTS-13 in newborn infants. J Thromb Haemost 2003 ; 2 : 228–233. [CrossRef]
  29. Sanchez-Luceros A, Farias CE, Amaral MM, et al. Von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004 ; 92 : 1320–1396. [PubMed]
  30. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008 ; 3 : 249–277. [CrossRef] [PubMed]
  31. Moschcovitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924 ; 24 : 21–24.
  32. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982 ; 307 : 1432–1435. [CrossRef] [PubMed]
  33. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 antibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005 ; 106 : 1262–1267. [CrossRef] [PubMed]
  34. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS13 antibodies feature (Ig isotype titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity. Blood 2007 ; 109 : 2815–2822. [PubMed]
  35. Scully M. Inhibitory anti-ADAMTS13 antibodies: measurement and clinical application. Blood Rev 2010 ; 24 : 11–16. [CrossRef] [PubMed]
  36. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010 ; 116 : 2005–2010. [CrossRef] [PubMed]
  37. Coppo P, Busson M, Veyradier A, et al. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost 2010 ; 8 : 856–859. [CrossRef] [PubMed]
  38. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS 13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008 ; 6 : 331–338. [PubMed]
  39. Coppo P, Benghoufa D, Veyradier A, et al. Prevalence and clinical significance of anti-nuclear antibodies in adult thrombotic microangiopathies. Medicine (Balt) 2004 ; 83 : 233–244. [CrossRef]
  40. Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010 ; 31 : 11–19. [CrossRef] [PubMed]
  41. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006 ; 107 : 118–125. [CrossRef] [PubMed]
  42. Westrick RJ, Ginsburg D.. Modifier genes for disorders of thrombosis and hemostasis. J Thromb Haemost 2009 ; 7 : (suppl 1) : 132–135. [CrossRef]
  43. Chauhan AK, Walsh MT, Zhu G, et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008 ; 111 : 3452–3457. [CrossRef] [PubMed]
  44. Plaimauer B, Kremer Hovinga J, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011 ; 9 : 936–944. [CrossRef] [PubMed]
  45. Laje P, Shang D, Cao W, et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood 2009 ; 113 : 2172–2180. [CrossRef] [PubMed]
  46. Niiya M, Endo M, Shang D, et al. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther 2009 ; 17 : 34–41. [CrossRef] [PubMed]
  47. Trionfini P, Tomasoni S, Galbusera M, et al. Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. Gene Ther 2009 ; 16 : 1373–1379. [CrossRef] [PubMed]
  48. Girma JP, Veyradier A, Meyer D. ADAMTS 13, la protéase spécifique du facteur Willebrand. Med Sci (Paris) 2002 ; 18 : 15–17. [CrossRef] [EDP Sciences]
  49. Chauhan AK, Kisucka J, Brill A, et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008 ; 205 : 2065–2074. [CrossRef] [PubMed]
  50. Fujioka M, Hayakawa K, MishimaK, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010 ; 115 : 1650–1653. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.